Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
StockNews.AI · 2 hours
AI Summary
Mineralys reported post hoc Launch-HTN results showing lorundrostat delivered meaningful blood pressure reductions and reduced albuminuria in CKD patients, with a favorable safety profile. CKD and non-CKD groups achieved SBP improvements, with 44% of CKD patients reaching SBP <130 mmHg versus 18% placebo, and a 52.2% UACR reduction in CKD with albuminuria. NDA review remains on track for December 2026, supporting a potential near-term regulatory catalyst.
Sentiment Rationale
The data show robust SBP reductions and meaningful UACR improvements in CKD, with favorable safety; FDA NDA clock started with a clear Dec 2026 target, elevating near-term sentiment and potential re-rating if data remain compelling or if FDA interactions are positive.
Trading Thesis
Bullish: potential NDA approval and expanded CKD label could drive MLYS in 6–12 months.
Market-Moving
- Post hoc Launch-HTN CKD data show meaningful SBP and albuminuria improvements.
- FDA NDA with PDUFA date of Dec 22, 2026 creates a near-term catalyst.
- Hyperkalemia rates are low, supporting favorable safety signals.
- CKD subset data indicate efficacy in high-risk patients on multiple meds.
Key Facts
- Launch-HTN CKD subset: SBP reductions -9.6 mmHg (CKD) vs -12.2 mmHg (non-CKD) at Week 12.
- CKD with albuminuria: 52.2% placebo-adjusted UACR reduction at 12 weeks.
- Lorundrostat shows favorable safety; hyperkalemia 2.4% in CKD, 0% in non-CKD.
- NDA review by FDA targeted for Dec 22, 2026; data bolster CKD hypertension treatment potential.
Companies Mentioned
- Mineralys Therapeutics, Inc. (MLYS): Primary subject; data could drive valuation and NDA progress.
- Tanabe Pharma Corporation (NotListed): Licensing partner; potential impact on IP access and commercialization terms.
Industry News
Category: Industry News. The release centers on late-stage clinical data and regulatory timing rather than earnings or strategic M&A, placing it in industry news affecting the broader cardiovascular/Kidney disease treatment landscape and potentially impacting MLYS's near-term valuation.